DrugPatentWatch Database Preview
SOOLANTRA Drug Profile
When do Soolantra patents expire, and when can generic versions of Soolantra launch?
Soolantra is a drug marketed by Galderma Labs Lp and is included in one NDA. There are twelve patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-nine patent family members in twenty-six countries.
The generic ingredient in SOOLANTRA is ivermectin. There are five drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the ivermectin profile page.
Summary for SOOLANTRA
| International Patents: | 59 |
| US Patents: | 12 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 64 |
| Clinical Trials: | 4 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for SOOLANTRA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SOOLANTRA |
| DailyMed Link: | SOOLANTRA at DailyMed |
Pharmacology for SOOLANTRA
| Drug Class | Antiparasitic Pediculicide |
Medical Subject Heading (MeSH) Categories for SOOLANTRA
Synonyms for SOOLANTRA
| (1'R,2R,4'S,10'E,14'E,16'E,21'R)-6-(butan-2-yl)-21',24'-dihydroxy-12'-{[(2R,4S,6S)-5-{[(2S,4S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-5,11',13',22'-tetramethyl-3',7',19'-trioxaspiro[oxa |
| (2ae,4e,5's,6s,6'r,7s,8e,11r,13r,15s,17ar,20r,20ar,20bs)-6'-[(2s)-Butan-2-Yl]-20,20b-Dihydroxy-5',6,8,19-Tetramethyl-17-Oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-Tetradecahydro-2h,7h-Spiro[11,15-Methanofuro[4,3,2-Pq][2, |
| (2R,5'S,6'R)-dihydroxy-[(2R,4S,5S,6S)-5-[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyl-tetrahydropyran-2-yl]oxy-4-methoxy-6-methyl-tetrahydropyran-2-yl]oxy-5'-tetramethyl-6'-[(1S)-1-methylpropyl]spiro[[?]-2,2'-tetrahydropyran]on |
| (Unlabeled)Ivermectin-d2 |
| 116522-39-5 |
| 123022-60-6 |
| 139645-33-3 |
| 22,23-Dihydro C-076B1 |
| 22,23-Dihydro-5-O-demethylavermectin A1a |
| 22,23-Dihydroavermectin B(1)a |
| 22,23-Dihydroavermectin B1|||Heartgard 30|||Ivomec|||Ivosint|||Mectizan|||Stromectol|||Uvemec|||Vermic|||Zimecterin |
| 22,23-Dihydroavermectin B1a |
| 288I867 |
| 5-O-demethyl-22,23-dihydroavermectin A1a |
| 70161-11-4 |
| 70288-86-7 |
| 71827-03-7 |
| 73910-57-3 |
| 91Y2202OUW |
| AB00513813 |
| AB00513813_04 |
| AB00513813-02 |
| AB00513813-03 |
| AB01563172_01 |
| AC1MJ4GR |
| AC1N7O27 |
| AKOS015969666 |
| AKOS027470116 |
| AS-14167 |
| Avermectin A1a, 22,23-dihydro-5-O-demethyl- |
| Avermectin A1a, 5-O-demethyl-22,23-dihydro- |
| avermectin H2B1a |
| AZSNMRSAGSSBNP-XPNPUAGNSA-N |
| BDBM50409816 |
| Bio-0055 |
| BPBio1_000322 |
| BRD-A48570745-001-01-1 |
| BRD-K24652731-001-02-7 |
| BRN 4643153 |
| BSPBio_000292 |
| C48H74O14 (B1a form) |
| CA011349 |
| CAS-71827-03-7 |
| CCG-204778 |
| CCG-213693 |
| CCG-220156 |
| CHEBI:63941 |
| CHEBI:91732 |
| CHEBI:94551 |
| CHEMBL1699565 |
| CHEMBL1876587 |
| CHEMBL263291 |
| D09YHJ |
| dihydro avermectin Bla |
| Dihydroavermectin B1a |
| DSSTox_CID_3181 |
| DSSTox_GSID_23181 |
| DSSTox_RID_76909 |
| DTXSID8023181 |
| EINECS 276-046-2 |
| EU-0100693 |
| FT-0082656 |
| GTPL2373 |
| H2B1a |
| Heartgard 30 |
| HMS1568O14 |
| HMS2089M09 |
| HMS2091E11 |
| HMS2095O14 |
| HMS2233J07 |
| HMS3262K07 |
| I 8898 |
| I1850 |
| IVERMECTIN |
| Ivermectin (MK-0933) |
| Ivermectin B1a |
| Ivermectin-d2 |
| Ivermectin, Antibiotic for Culture Media Use Only |
| Ivermectin, European Pharmacopoeia (EP) Reference Standard |
| Ivermectin, pharmaceutical secondary standard; traceable to USP, PhEur, BP |
| Ivermectin, United States Pharmacopeia (USP) Reference Standard |
| IvermectinB1a |
| Ivexterm (TN) |
| IVM |
| Ivosint |
| J10179 |
| Lopac0_000693 |
| LP00693 |
| Mectizan (TN) |
| MK-933 |
| MLS001333247 |
| MLS001333248 |
| MLS002153248 |
| MolPort-006-394-715 |
| MolPort-020-015-936 |
| MolPort-044-878-307 |
| NCGC00094047-01 |
| NCGC00094047-02 |
| NCGC00163233-01 |
| NCGC00186639-01 |
| NCGC00261378-01 |
| NSC-755843 |
| NSC755843 |
| Pharmakon1600-01300027 |
| Prestwick_516 |
| Prestwick2_000156 |
| Prestwick3_000156 |
| Q-201262 |
| RL04692 |
| s1351 |
| SCHEMBL13259385 |
| SCHEMBL17212450 |
| SCHEMBL312795 |
| Sklice |
| SMR000857211 |
| SR-01000075941 |
| SR-01000075941-1 |
| Stromectol (TN) |
| Tox21_112034 |
| Tox21_500693 |
| UNII-8883YP2R6D component AZSNMRSAGSSBNP-XPNPUAGNSA-N |
| UNII-91Y2202OUW |
| VA11120 |
| ZINC238808778 |
| ZINC252286706 |
| ZINC253630390 |
| ZINC301054281 |
US Patents and Regulatory Information for SOOLANTRA
Expired US Patents for SOOLANTRA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Galderma Labs Lp | SOOLANTRA | ivermectin | CREAM;TOPICAL | 206255-001 | Dec 19, 2014 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for SOOLANTRA
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Cream | 1% | ➤ Subscribe | ➤ Try a Free Trial |
International Patents for SOOLANTRA
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Japan | 2006524212 | ➤ Try a Free Trial |
| Hong Kong | 1223842 | ➤ Try a Free Trial |
| Canada | 2916704 | ➤ Try a Free Trial |
| Mexico | PA05011208 | ➤ Try a Free Trial |
| European Patent Office | 3019173 | ➤ Try a Free Trial |
| Canada | 2522579 | ➤ Try a Free Trial |
| Poland | 378932 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for SOOLANTRA
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C0069 | France | ➤ Try a Free Trial | PRODUCT NAME: IVERMECTINE; NAT. REGISTRATION NO/DATE: NL 44511 20150721; FIRST REGISTRATION: MT - MA 117/01101 20150402 |
| 915 | Luxembourg | ➤ Try a Free Trial | PRODUCT NAME: IVERMECTINE POUR SON USAGE DANS LE TRAITEMENT DE LA ROSACEA; FIRST REGISTRATION: 20150402 |
| /2015 | Austria | ➤ Try a Free Trial | PRODUCT NAME: IVERMECTIN; NAT. REGISTRATION NO/DATE: 136170 20150602; FIRST REGISTRATION: MT MA 117/01101 20150402 |
| 2015 00045 | Denmark | ➤ Try a Free Trial | PRODUCT NAME: IVERMECTIN, 22, 23-DIHYDROAVERMECTINB1A + 22,23-DIHRODROAVERMECTIN B1B FOR USE IN THE TREATMNET OF RESACEA; NAT. REG. NO/DATE: 54123 20150422; FIRST REG. NO/DATE: MT MA 117/01101 20150402 |
| 0756 | Netherlands | ➤ Try a Free Trial | PRODUCT NAME: IVERMECTINE VOOR TOEPASSING IN DE BEHANDELING VAN ROSACEA; FIRST REGISTRATION NO/DATE: MA117/01101 20150402; NATIONAL REGISTRATION NO/DATE: RVG 115310 20150504 |
| 15/046 | Ireland | ➤ Try a Free Trial | PRODUCT NAME: IVERMECTIN; NAT REGISTRATION NO/DATE: PA0590/028/001 20150424; FIRST REGISTRATION NO/DATE: MA117/01101 20150402 |
| 2015000079 | Germany | ➤ Try a Free Trial | PRODUCT NAME: IVERMECTIN ZU SEINER VERWENDUNG FUER DIE BEHANDLUNG VON ROSAZEA; NAT. REGISTRATION NO/DATE: 92429.00.00 20150429; FIRST REGISTRATION: MALTA MA 117/01101 20150402 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
